Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash from Financing Activities (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Cash from Financing Activities for 6 consecutive years, with -$8.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 2191.83% year-over-year to -$8.5 million, compared with a TTM value of -$5.8 million through Dec 2025, down 56.93%, and an annual FY2025 reading of -$5.8 million, down 56.93% over the prior year.
  • Cash from Financing Activities was -$8.5 million for Q4 2025 at Viemed Healthcare, down from $5.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $11.3 million in Q2 2023 and bottomed at -$8.5 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is -$1.4 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities surged 301.72% in 2023, then crashed 3535.9% in 2024.
  • Year by year, Cash from Financing Activities stood at -$551000.0 in 2021, then plummeted by 783.85% to -$4.9 million in 2022, then soared by 37.78% to -$3.0 million in 2023, then soared by 113.33% to $404000.0 in 2024, then tumbled by 2191.83% to -$8.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for VMD at -$8.5 million in Q4 2025, $5.0 million in Q3 2025, and -$671000.0 in Q2 2025.